Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Affordable menopause relief is on the way. The FDA has approved the first generic version of Climara Pro, a once-weekly skin patch that delivers both estradiol and levonorgestrel to treat moderate-to-severe hot flashes, night sweats, and help prevent osteoporosis. Made by Zydus Pharmaceuticals, the generic is expected to boost competition and lower costs for the millions of women who rely on hormone therapy.
Affordable menopause relief is on the way. The FDA has approved the first generic version of Climara Pro, a once-weekly transdermal patch that combines estradiol (0.045 mg/day) and levonorgestrel (0.015 mg/day) to treat moderate-to-severe menopausal symptoms and prevent osteoporosis. Made by Zydus Pharmaceuticals, the patch works identically to the Bayer brand-name version and is approved for postmenopausal women who still have a uterus.
The combo formula matters: estrogen alone can cause the uterine lining to thicken abnormally, raising the risk of uterine cancer. Adding levonorgestrel, a progestin, provides a protective counterbalance. The approval also comes amid a broader FDA push to expand generic drug access and address ongoing estradiol patch supply shortages.
Key Takeaways:
Why it matters: With 9-in-10 U.S. prescriptions filled as generics, this approval could meaningfully lower costs and expand access to a proven menopause treatment for a large and underserved patient population.
